Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOMIC2: Azithromycin versus usual care in ambulatory COVID-19
2020-001740-26Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoint: Composite of death or hospital admission with respiratory failure requiring NIV or IMV by day 28. Status: unknown.
02
Drugs
azithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001740-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001740-26.